论文部分内容阅读
乙基西索米星为一新的半合成氨基糖苷抗生素类,对需氧革蓝氏阴性杆菌具有良好抗菌作用,尤其是某些庆大霉素、妥布拉霉素耐药菌株对其仍可呈现敏感;对产酶金葡菌亦具有高度抗菌活性。乙基西索米星的另一突出优点是它在氨基糖苷抗生素类中是耳、肾毒性发生率最低者。1976年国外由西索米星半合成本品,1980～1981年较大规模进行了临床应用,治疗敏感革蓝氏阴性杆菌感染安全而有效,国内目前正在研制中。本文报告乙基西索米星首次在国内应用于健康志愿者的药物代谢动力学研究,以及据此而拟定的给药方案,旨在为今后此药临床安全有效应用提供可靠的科学依据。
Ethyl Sisomicin is a new class of semi-synthetic aminoglycoside antibiotics, which has good antibacterial activity against Aeromonas hydrophila, especially some gentamycin and tobramycin resistant strains. Can be rendered sensitive; Staphylococcus aureus also has a high degree of antibacterial activity. Another prominent advantage of ethyl sisomicin is that it is the ear aminoglycoside antibiotics, the lowest incidence of nephrotoxicity. In 1976, the product was semisynthetic synthesized by sisomicin abroad, and its clinical application was carried out on a large scale from 1980 to 1981. The treatment of sensitive gram-negative bacilli is safe and effective. It is currently under development. This paper reports the first time that Ethyl Sisomicin is applied to the study of pharmacokinetics in healthy volunteers in China and the dosing schedule based on it. The aim is to provide a reliable scientific basis for the safe and effective clinical use of Ethyl Sisomicin in the future.